Opinion|Videos|February 7, 2025
Opportunities for Easing BTK Inhibitor Switches
Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of multiple challenges including optimal timing of the switch, potential washout periods, dose adjustments, patient education about expected adverse effects, and close monitoring during the transition period to maintain treatment efficacy while minimizing complications.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What challenges do you face when switching between BTK inhibitors, and what strategies can help mitigate these challenges?
- How can oncologists better educate patients about the potential for switching BTK inhibitors to manage toxicities without compromising treatment outcomes?
Advertisement
Related to this article
October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.
A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
From taladegib to admilparant and inhaled treprostinil, here are the key 2026 advances in idiopathic pulmonary fibrosis care.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
Real-world data show antifibrotic dose reductions in IPF were not significantly linked to faster disease progression vs staying on full dose.
Naim Alkhouri, MD, on real-world resmetirom results, when biopsy is still needed, choosing a GLP-1 or resmetirom, and access barriers in MASH
Advertisement
Advertisement
Trending on AJMC
1
Four Major Idiopathic Pulmonary Fibrosis Advances From 2026
2
As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround
3
Birth Weight, Childhood Weight Gain Linked to Non-Hodgkin Lymphoma Risk
4
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
5